Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins

Journal of Medicinal Chemistry

Volumn 46, Issue 20, 2003, Pages 4259-4264

  Kitada, Shinichi ^a   Leone, Marilisa ^a   Sareth, Sina ^a   Zhai, Dayong ^a   Reed, John C ^a   Pellecchia, Maurizio ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GOSSYPOL; NATURAL PRODUCT; POLYPHENOL DERIVATIVE; PROTEIN BCL 2; PROTEIN BCL XL; PURPUROGALLIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; DRUG MECHANISM; DRUG PROTEIN BINDING; FLUORESCENCE POLARIZATION; HUMAN; HUMAN CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; BCL-X PROTEIN; BENZOCYCLOHEPTENES; BINDING SITES; CELL SURVIVAL; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FLAVONOIDS; GOSSYPOL; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PHENOLS; POLYMERS; PROTO-ONCOGENE PROTEINS C-BCL-2; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0141569444     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030190z     Document Type: Article

References (34)

1. Reed, J. C. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr. Opin. Oncol 1995, 7, 541-546.
2. Kelekar, A.; Thompson, C. B. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol. 1998, 8, 324-330.
3. Johnstone, R. W.; Ruefli, A. A.; Lowe, S. W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108, 153-164.
4. Olopade, O. I.; Adeyanju, M. O.; Safa, A. R.; Hagos, F.; Mick, R.; et al. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J. Sci. Am. 1997, 3, 230-237.
5. Reeve, J. G.; Xiong, J.; Morgan, J.; Bleehen, N. M. Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Br. J. Cancer 1996, 73, 1193-1200.
6. Wang, J. L.; Liu, D.; Zhang, Z. J.; Shan, S.; Han, X.; et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 7124-7129.
7. Degterev, A.; Lugovskoy, A.; Cardone, M.; Mulley, B.; Wagner, G.; et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat. Cell Biol. 2001, 3, 173-182.
8. Tzung, S. P.; Kim, K. M.; Basanez, G.; Giedt, C. D.; Simon, J.; et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat. Cell Biol. 2001, 3, 183-191.
9. Enyedy, I. J.; Ling, Y.; Nacro, K.; Tomita, Y.; Wu, X.; et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J. Med. Chem. 2001, 44, 4313-4324.
10. Kaneko, M.; Nakashima, T.; Uosaki, Y.; Hara, M.; Ikeda, S.; et al. Synthesis of tetrocarcin derivatives with specific inhibitory activity towards Bcl-2 functions. Bioorg. Med. Chem. Lett. 2001, 11, 887-890.
11. Chin, J. W.; Schepartz, A. Design and Evolution of a Miniature Bcl-2 Binding Protein. Angew. Chem., Int. Ed. 2001, 40, 3806-3809.
12. Kutzki, O.; Park, H. S.; Ernst, J. T.; Orner, B. P.; Yin, H.; et al. Development of a potent Bcl-x(L) antagonist based on α-helix mimicry. J. Am. Chem. Soc. 2002, 124, 11838-11839.
13. Wu, D. An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive agent and in gynaecological disease. Drugs 1989, 38, 333-341.
14. Gilbert, N. E.; O'Reilly, J. E.; Chang, C. J.; Lin, Y. C.; Brueggemeier, R. W. Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. Life Sci. 1995, 57, 61-67.
15. Wu, Y. W.; Chik, C. L.; Knazek, R. A. An in vitro and in vivo study of antitumor effects of gossypol on human SW-13 adrenocortical carcinoma. Cancer Res. 1989, 49, 3754-3758.
16. Thomas, M.; von Hagen, V.; Moustafa, Y.; Montmasson, M. P.; Monet, J. D. Effects of gossypol on the cell cycle phases in T-47D human breast cancer cells. Anticancer Res. 1991, 11, 1469-1475.
17. Wang, X. Cytotoxic effect of gossypol in the treatment of metastic adrenal cancer. J. Clin. Endocrinol. Metab. 1993, 76, 1019-1024.
18. Leblanc, M. L.; Russo, J.; Kudelka, A. P.; Smith, J. A. An in Vitro Study of Inhibitory Activity of Gossypol, a Cottonseed Extract, in Human Carcinoma Cell Lines. Pharmacol. Res. 2002, 46, 551-555.
19. Stein, R. C.; Joseph, A. E.; Matlin, S. A.; Cunningham, D. C.; Ford, H. T.; Coombes, R. C. A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother. Pharmacol. 1992, 30, 480-482.
20. Van Poznak, C.; Seidman, A. D.; Reidenberg, M. M.; Moasser, M. M.; Sklarin, N.; et al. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res. Treat. 2001, 66, 239-248.
21. Wang, X.; Wang, J,; Wong, S. C.; Chow, L. S.; Nicholls, J. M.; et al. Cytotoxic effect of gossypol on colon carcinoma cells. Life Sci. 2000, 67, 2663-2671.
22. Sattler, M.; Liang, H.; Nettesheim, D.; Meadows, R. P.; Harlan, J. E.; et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997, 275, 983-986.
23. Deveraux, Q. L.; Reed, J. C. IAP family proteins - suppressors of apoptosis. Genes Dev. 1999, 13, 239-252.
24. Anderson, W. A. Hydroxylic aromatic compounds as additives for rubber based, composite solid propellant. U.S. Patent 4,181,-545, 1980 (United Technologies Corporation).
25. Abou-Karam, M.; Shier, W. T. Inhibition of oncogene product enzyme activity as an approach to cancer chemoprevention. Tyrosine-specific protein kinase inhibition by purpurogallin from Quercus sp. nutgall. Phytother. Res. 1999, 13, 337-340.
26. Fung, K. P.; Wu, T. W.; Lui, C. P. Purpurogallin inhibits DNA synthesis of murine fibrosarcoma L-929 and human U-87 MG glioblastoma cells in vitro. Chemotherapy 1996, 42, 199-205.
27. Pellecchia, M.; Sem, D. S.; Wüthrich, K. NMR in drug discovery. Nat. Rev. Drug Discovery 2002, 1, 211-219
28. Hajduk, P. J.; Olejniczak, E. T.; Fesik, S. W. One-dimensional relaxation- and diffusion-edited NMR methods for screening compounds that bind to macromolecules. J. Am. Chem. Soc. 1997, 119, 12257-12261.
29. Dalvit, C.; Pevarello, P.; Tato, M.; Veronesi, M.; Vulpetti, A.; et al. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J. Biomol. NMR 2000, 18, 65-68.
30. Kramer, B.; Rarey, M.; Lengauer, T. Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins 1999, 37, 228-241.
31. Qiu, J.; Levin, L. R.; Buck, J.; Reidenberg, M. M. Different pathways of cell killing by gossypol enantiomers. Exp Biol Med (Maywood) 2002, 227, 398-401.
32. Pervushin, K.; Riek, R.; Wider, G.; Wüthrich, K. Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 12366-12371.
33. Koradi, R.; Billeter, M.; Wüthrich, K. MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graphics 1996, 14, 51-55.
34. Weislow, O. S.; Kiser, R.; Fine, D. L.; Bader, J.; Shoemaker, R. H.; et al. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 1989, 81, 577-586.